The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis

Compared with SNV (2) fusion neoantigens tend to have notably higher immunogenic potentials than SNV (3) fusion candidate neoantigens distribute sparsely between individual patients. Although several recurrent candidate neoantigens exist, they usually have extremely low immunogenic potentials, suggesting that vaccination-based cancer immunotherapy must be personalized; (4) compared with fusion mutations involving tumor passenger genes, fusion mutations involving oncogenic genes have remarkably low immunogenic potentials, indicating that they undergo selection pressure during tumorigenesis.